全文获取类型
收费全文 | 3688篇 |
免费 | 273篇 |
国内免费 | 273篇 |
出版年
2024年 | 2篇 |
2023年 | 44篇 |
2022年 | 65篇 |
2021年 | 191篇 |
2020年 | 124篇 |
2019年 | 149篇 |
2018年 | 154篇 |
2017年 | 99篇 |
2016年 | 152篇 |
2015年 | 242篇 |
2014年 | 243篇 |
2013年 | 301篇 |
2012年 | 346篇 |
2011年 | 284篇 |
2010年 | 161篇 |
2009年 | 189篇 |
2008年 | 225篇 |
2007年 | 192篇 |
2006年 | 153篇 |
2005年 | 126篇 |
2004年 | 121篇 |
2003年 | 106篇 |
2002年 | 86篇 |
2001年 | 68篇 |
2000年 | 62篇 |
1999年 | 67篇 |
1998年 | 34篇 |
1997年 | 39篇 |
1996年 | 22篇 |
1995年 | 26篇 |
1994年 | 17篇 |
1993年 | 18篇 |
1992年 | 19篇 |
1991年 | 10篇 |
1990年 | 18篇 |
1989年 | 12篇 |
1988年 | 18篇 |
1987年 | 7篇 |
1986年 | 8篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1979年 | 2篇 |
1975年 | 2篇 |
1973年 | 2篇 |
1969年 | 1篇 |
1949年 | 1篇 |
1948年 | 1篇 |
排序方式: 共有4234条查询结果,搜索用时 31 毫秒
61.
62.
63.
64.
Aidi injection (ADI), a traditional Chinese biomedical preparation, is a promising adjuvant therapy for gynecologic tumors (GTs), including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC). Although studies have reported positively on ADI therapy, its exact effects and safety in GT patients remain controversial. Therefore, a wide-ranging systematic search of electronic databases was performed for this meta-analysis. Data from 38 trials including 3309 GT patients were analyzed. The results indicated that the combination of conventional treatment and ADI markedly improved the patients’ overall response rate (P<0.00001), disease control rate (P<0.00001), and quality of life (P<0.05) compared with conventional treatment alone. Furthermore, patient immunity was enhanced with combined treatment, as indicated by significantly increased percentages of CD3+ (P=0.005) and CD4+ (P<0.00001) and increased CD4+/CD8+ ratio (P=0.001). Most of the adverse events caused by radiochemotherapy such as gastrointestinal issues, leukopenia, thrombocytopenia, and hepatotoxicity, (P<0.05 for all) were significantly alleviated when ADI was used in the GT patients. However, other adverse events such as nephrotoxicity, diarrhea, alopecia, and neurotoxicity did not significantly differ between the two groups. Overall, these results suggest that the combination of conventional and ADI treatment is more effective than conventional treatment alone. 相似文献
65.
66.
67.
68.
69.
70.
Xiaolei Chen Yue Wang Ning Qu Bing Zhang Chun Xia 《Journal of cellular and molecular medicine》2021,25(3):1531-1545
Previous studies identified the involvement of phosphoinositide-specific phospholipase C (PLC) γ1 in some events of chondrocytes. This study aims to investigate whether and how PLCγ1 modulates autophagy to execute its role in osteoarthritis (OA) progression. Rat normal or human OA chondrocytes were pretreated with IL-1β for mimicking or sustaining OA pathological condition. Using Western blotting, immunoprecipitation, qPCR, immunofluorescence and Dimethylmethylene blue assays, and ELISA and transmission electron microscope techniques, we found that PLCγ1 inhibitor U73122 enhanced Collagen II, Aggrecan and GAG levels, accompanied with increased LC3B-II/I ratio and decreased P62 expression level, whereas autophagy inhibitor Chloroquine partially diminished its effect. Meanwhile, U73122 dissociated Beclin1 from Beclin1-IP3R-Bcl-2 complex and blocked mTOR/ULK1 axis, in which the crosstalk between PLCγ1, AMPK, Erk and Akt were involved. Additionally, by haematoxylin and eosin, Safranin O/Fast green, and immunohistochemistry staining, we observed that intra-articular injection of Ad-shPLCγ1-1/2 significantly enhanced Collagen and Aggrecan levels, accompanied with increased LC3B and decreased P62 levels in a rat OA model induced by anterior cruciate ligament transection and medial meniscus resection. Consequently, PLCγ1 inhibition-driven autophagy conferred cartilage protection against OA through promoting ECM synthesis in OA chondrocytes in vivo and in vitro, involving the crosstalk between PLCγ1, AMPK, Erk and Akt. 相似文献